Cargando…
Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma
Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration int...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493242/ https://www.ncbi.nlm.nih.gov/pubmed/36159816 http://dx.doi.org/10.3389/fimmu.2022.986615 |
_version_ | 1784793660441755648 |
---|---|
author | Fan, Yang Gao, Zijie Xu, Jianye Wang, Huizhi Guo, Qindong Xue, Hao Zhao, Rongrong Guo, Xing Li, Gang |
author_facet | Fan, Yang Gao, Zijie Xu, Jianye Wang, Huizhi Guo, Qindong Xue, Hao Zhao, Rongrong Guo, Xing Li, Gang |
author_sort | Fan, Yang |
collection | PubMed |
description | Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration into the tumor microenvironment (TME), and stemness characteristics. SNHG interaction patterns were determined based on 25 SNHGs and systematically correlated with GBM subtypes, TME and stemness characteristics. The SNHG interaction score (SNHGscore) model was generated to quantify SNHG interaction patterns. The high SNHGscore group was characterized by a poor prognosis, the mesenchymal (MES) subtype, the infiltration of suppressive immune cells and a differentiated phenotype. Further analysis indicated that high SNHGscore was associated with a weaker response to anti-PD-1/L1 immunotherapy. Tumor cells with high SNHG scores were more sensitive to drugs targeting the EGFR and ERK-MAPK signaling pathways. Finally, we assessed SNHG interaction patterns in multiple cancers to verify their universality. This is a novel and comprehensive study that provides targeted therapeutic strategies based on SNHG interactions. Our work highlights the crosstalk and potential clinical utility of SNHG interactions in cancer therapy. |
format | Online Article Text |
id | pubmed-9493242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94932422022-09-23 Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma Fan, Yang Gao, Zijie Xu, Jianye Wang, Huizhi Guo, Qindong Xue, Hao Zhao, Rongrong Guo, Xing Li, Gang Front Immunol Immunology Glioblastoma (GBM) patients exhibit high mortality and recurrence rates despite multimodal therapy. Small nucleolar RNA host genes (SNHGs) are a group of long noncoding RNAs that perform a wide range of biological functions. We aimed to reveal the role of SNHGs in GBM subtypes, cell infiltration into the tumor microenvironment (TME), and stemness characteristics. SNHG interaction patterns were determined based on 25 SNHGs and systematically correlated with GBM subtypes, TME and stemness characteristics. The SNHG interaction score (SNHGscore) model was generated to quantify SNHG interaction patterns. The high SNHGscore group was characterized by a poor prognosis, the mesenchymal (MES) subtype, the infiltration of suppressive immune cells and a differentiated phenotype. Further analysis indicated that high SNHGscore was associated with a weaker response to anti-PD-1/L1 immunotherapy. Tumor cells with high SNHG scores were more sensitive to drugs targeting the EGFR and ERK-MAPK signaling pathways. Finally, we assessed SNHG interaction patterns in multiple cancers to verify their universality. This is a novel and comprehensive study that provides targeted therapeutic strategies based on SNHG interactions. Our work highlights the crosstalk and potential clinical utility of SNHG interactions in cancer therapy. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9493242/ /pubmed/36159816 http://dx.doi.org/10.3389/fimmu.2022.986615 Text en Copyright © 2022 Fan, Gao, Xu, Wang, Guo, Xue, Zhao, Guo and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Fan, Yang Gao, Zijie Xu, Jianye Wang, Huizhi Guo, Qindong Xue, Hao Zhao, Rongrong Guo, Xing Li, Gang Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title_full | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title_fullStr | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title_full_unstemmed | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title_short | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
title_sort | identification and validation of snhg gene signature to predict malignant behaviors and therapeutic responses in glioblastoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493242/ https://www.ncbi.nlm.nih.gov/pubmed/36159816 http://dx.doi.org/10.3389/fimmu.2022.986615 |
work_keys_str_mv | AT fanyang identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT gaozijie identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT xujianye identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT wanghuizhi identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT guoqindong identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT xuehao identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT zhaorongrong identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT guoxing identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma AT ligang identificationandvalidationofsnhggenesignaturetopredictmalignantbehaviorsandtherapeuticresponsesinglioblastoma |